Prevalence of vernal keratoconjunctivitis: a rare disease?
- PMID: 18356259
- DOI: 10.1136/bjo.2007.117812
Prevalence of vernal keratoconjunctivitis: a rare disease?
Abstract
Objective: To determine the prevalence of vernal keratoconjuntivitis (VKC) in Europe.
Methods: A cross-sectional survey was mailed to 3003 ophthalmologists from six countries (Finland, France, Italy, The Netherlands, Norway and Sweden) representing 151.9 million inhabitants. Results were analysed per country, and VKC prevalence for the 15 European member states in 2002 was extrapolated. Six hypotheses were used: disease duration (4 or 8 years) combined with three prevalence hypotheses for non-responding ophthalmologists.
Results: The response rate to the survey was 29.5%. The estimates of VKC prevalence in Western Europe (per 10,000 inhabitants) ranged from 1.16 to 10.55. The prevalence of VKC with corneal complications ranged from 0.30 to 2.26. The VKC prevalences per country were in the following ranges: Italy 2.4-27.8, Finland, 0.7-8.4, Sweden 1.2-8.7, The Netherlands 0.6-4.6, France 0.7-3.3 and Norway 0.3-1.9. VKC with corneal complications were: Italy 0.4-4.8, Sweden 0.3-2.4, Finland 0.2-2.8, The Netherlands 0.2-1.6, France 0.3-1.4 and Norway 0.1-1.0.
Conclusions: Based on the most likely hypotheses concerning disease duration and non-responding ophthalmologists' VKC case rate, the best estimate of VKC prevalence in Western Europe is 3.2/10,000 inhabitants. The prevalence of VKC with corneal complications is 0.8/10,000 inhabitants.
Similar articles
-
Vernal keratoconjunctivitis in school children in Rwanda: clinical presentation, impact on school attendance, and access to medical care.Ophthalmology. 2012 Sep;119(9):1766-72. doi: 10.1016/j.ophtha.2012.03.041. Epub 2012 Jun 7. Ophthalmology. 2012. PMID: 22683059
-
Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population.Ophthalmic Epidemiol. 2009 Jan-Feb;16(1):38-41. doi: 10.1080/09286580802573177. Ophthalmic Epidemiol. 2009. PMID: 19191180
-
Vernal keratoconjunctivitis: modes of presentation in Nepalese population.Kathmandu Univ Med J (KUMJ). 2007 Oct-Dec;5(4):526-30. Kathmandu Univ Med J (KUMJ). 2007. PMID: 18604088
-
Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape.Surv Ophthalmol. 2024 Mar-Apr;69(2):265-278. doi: 10.1016/j.survophthal.2023.10.008. Epub 2023 Oct 26. Surv Ophthalmol. 2024. PMID: 37890678 Review.
-
Vernal keratoconjunctivitis and keratoconus.Curr Opin Allergy Clin Immunol. 2021 Oct 1;21(5):507-514. doi: 10.1097/ACI.0000000000000765. Curr Opin Allergy Clin Immunol. 2021. PMID: 34269743 Review.
Cited by
-
To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital.Indian J Pharmacol. 2020 Nov-Dec;52(6):476-481. doi: 10.4103/ijp.IJP_174_20. Indian J Pharmacol. 2020. PMID: 33666188 Free PMC article.
-
Allergic conjunctivitis: a comprehensive review of the literature.Ital J Pediatr. 2013 Mar 14;39:18. doi: 10.1186/1824-7288-39-18. Ital J Pediatr. 2013. PMID: 23497516 Free PMC article. Review.
-
Air pollution significantly associated with severe ocular allergic inflammatory diseases.Sci Rep. 2019 Dec 3;9(1):18205. doi: 10.1038/s41598-019-54841-4. Sci Rep. 2019. PMID: 31796815 Free PMC article.
-
Corneal biochemical features of patients with vernal keratoconjunctivitis.Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):555-8. doi: 10.1007/s00417-012-2089-2. Epub 2012 Jun 22. Graefes Arch Clin Exp Ophthalmol. 2013. PMID: 22722471
-
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy.Clin Ophthalmol. 2019 Jul 5;13:1147-1155. doi: 10.2147/OPTH.S181811. eCollection 2019. Clin Ophthalmol. 2019. PMID: 31308622 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources